Topical CBD for Skin Health

(cannabidiol Trial)

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Penn State University

Disqualifiers: Abnormal heart rate, Diabetes, Nicotine, others

Approved in 3 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 1

Duration: 1 day

Trial Summary

What is the purpose of this trial?

Cannabidiol, or CBD, is an over-the-counter "nutraceutical" that is more commonly being used by healthy adults for pain management, recovery from strenuous exercise, and general wellness. However, little research exists on the effects of CBD in otherwise healthy individuals. This study uses iontophoresis, a common technique used in physical therapy, to determine the effectiveness of topical CBD in lessening the reflex increased cutaneous vascular conductance response to stimulation of the skin.

Eligibility Criteria

This trial is for English-speaking men and women aged 18 or older with a BMI ≤ 39.9 and normal blood sugar levels (HbA1C <6.5%). It's not suitable for those with diabetes, drug use, pregnant/breastfeeding women, abnormal heart rates/BP, skin conditions/allergies, nicotine users, or recent CBD users.

Inclusion Criteria

English speaking

Normal HbA1C of <6.5%

My BMI is 39.9 or less.

Exclusion Criteria

Abnormal resting heart rate (<60 or >100 bpm) or BP (systolic <100 or >129 mmHg, diastolic <60 or >100 mmHg) values

Known skin allergies

I have diabetes.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive topical application of CBD or placebo and undergo iontophoresis to assess vascular reactivity

1 day

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

1 week

Treatment Details

Interventions

• Cannabidiol

Trial Overview The study tests the effect of topical Cannabidiol (CBD) on skin vascular reactivity using iontophoresis in healthy adults. The goal is to see if CBD can reduce the increased blood flow response that happens when the skin is stimulated.

Participant Groups

Group I: Cannabidiol Experimental Treatment 1 Intervention

Active ingredient experimental arm, contains full spectrum connabidiol

Group II: Placebo Placebo Group 1 Intervention

Vehicle control, does not contain cannabidiol

Who Is Running the Clinical Trial?

Penn State University

Lead Sponsor

Trials

380

Recruited

131,000+